Product Description

Molnunat contains Molnupiravir 200 mg, an oral antiviral used to treat adults with mild to moderate COVID-19 who are at high risk for progressing to severe illness. It works by disrupting the virus’s replication process, helping to lower the viral load in the body.

Molnunat is effective when started early—within 5 days of symptom onset—and is available by prescription only.

Key Benefits

• Reduces risk of hospitalization and severe illness
• Convenient oral capsule – no IV or injection required
• Effective across multiple COVID-19 variants
• Short 5-day treatment course
• Well-tolerated in most patients

Product Information

• Brand: Molnunat
• Generic Name: Molnupiravir
• Strength: 200 mg per capsule
• Form: Oral capsule
• Typical Pack: 40 capsules (5-day course)
• Route of Administration: Oral
• Storage: Store below 30°C in a cool, dry place

Dosage & Administration

• Standard dose: 800 mg (4 capsules) every 12 hours
• Course duration: 5 days (40 capsules total)
• Start treatment within 5 days of symptom onset
• Take with or without food
• Do not skip or double doses

Precautions & Warnings

• Not recommended during pregnancy or breastfeeding
• Use effective contraception during and after treatment (men: 3 months, women: 4 days)
• Not intended for individuals under 18 years of age
• Consult your doctor before use if you have liver or kidney conditions
• Do not share the medication with others

FAQs

1. What is Molnunat 200 mg used for?

Molnunat is used to treat mild to moderate COVID-19 in adults who are at risk of progressing to severe illness.

2. When should I start taking it?

Treatment must begin within 5 days of symptom onset for it to be effective.

3. Can pregnant or breastfeeding women take Molnunat?

No, it is not recommended due to potential risks to the fetus or infant.

4. Are there any common side effects?

Possible side effects include headache, nausea, diarrhea, and dizziness. Most are mild and temporary.

5. Do I need a prescription to buy Molnunat?

Yes, this medication should only be used under the supervision of a qualified healthcare provider.